Drug Information

Drug General Information
Drug ID
D02YKI
Former ID
DIB002902
Drug Name
PF-04995274
Drug Type
Small molecular drug
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 1 [523152]
Company
Pfizer Inc
Formula
C23H32N2O6
Canonical SMILES
C1CN(CCC1COC2=NOC3=C2C(=CC=C3)OC4CCOC4)CC5(CCOCC5)O
InChI
1S/C23H32N2O6/c26-23(7-12-27-13-8-23)16-25-9-4-17(5-10-25)14-29-22-21-19(30-18-6-11-28-15-18)2-1-3-20(21)31-24-22/h1-3,17-18,26H,4-16H2/t18-/m1/s1
InChIKey
WLLOFQROROXOMO-GOSISDBHSA-N
PubChem Compound ID
53354764
PubChem Substance ID
125239007, 163313297, 163347622, 172650872, 198969007, 226920854
Target and Pathway
Target(s) 5-hydroxytryptamine 4 receptor Target Info Agonist [550239]
KEGG Pathway Calcium signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT4 type receptor mediated signaling pathway
PathWhiz Pathway Excitatory Neural Signalling Through 5-HTR 4 and Serotonin
Reactome Serotonin receptors
G alpha (s) signalling events
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 523152ClinicalTrials.gov (NCT01193062) Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274. U.S. National Institutes of Health.
Ref 550239Pharmacokinetics, safety and tolerability of PF04995274: A 5HT4 partial agonist being developed for the treatment of Alzheimer's disease. Alzheimer's and Dementia.